Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).

Pediatric rheumatology online journal·2026
Same author

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same author

A scoping review of digital psychosocial interventions for sleep disturbances in children with chronic health conditions.

Sleep medicine·2026
Same author

Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.

Annals of the rheumatic diseases·2026
Same author

STING-STAT3-SOX18 Axis Drives EndMT and Epigenetic Reprogramming in SAVI Lung Fibrosis.

bioRxiv : the preprint server for biology·2026
Same author

Systematic Literature Review Informing Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-Endorsed Recommendations for the Treat-to-Target Strategy in Juvenile Dermatomyositis.

The Journal of rheumatology·2026

Related Experiment Video

Updated: May 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus

Norman T Ilowite1, Christy I Sandborg, Brian M Feldman

  • 1Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA. nilowite@montefiore.org.

Pediatric Rheumatology Online Journal
|August 31, 2012
PubMed
Summary
This summary is machine-generated.

This study developed a consensus-based algorithm to standardize corticosteroid dosing in rheumatology trials, specifically for the Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT). The algorithm provides clear criteria for initiating, increasing, and tapering corticosteroid therapy.

More Related Videos

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
07:12

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis

Published on: February 10, 2026

Related Experiment Videos

Last Updated: May 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
07:12

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis

Published on: February 10, 2026

Area of Science:

  • Rheumatology
  • Clinical Trials
  • Pharmacology

Background:

  • Managing background corticosteroid therapy in rheumatology clinical trials presents significant challenges.
  • Standardizing corticosteroid dosing is crucial for trial integrity and patient outcomes.
  • The Randomized Placebo Phase Study of Rilonacept in Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT) required a standardized approach.

Purpose of the Study:

  • To describe the consensus methodology used to design a corticosteroid dosing algorithm.
  • To standardize corticosteroid management within the RAPPORT clinical trial.
  • To establish clear criteria for corticosteroid initiation, increase, and tapering.

Main Methods:

  • A modified Delphi Method was employed, involving an expert panel of 20 principal investigators and 4 topic specialists.
  • The consensus process included an online questionnaire followed by a face-to-face meeting.
  • Consensus was defined as ≥75% agreement, with majority vote for unresolved critical items.

Main Results:

  • Criteria for initiating or increasing corticosteroids were identified, including specific clinical indicators like anemia, myocarditis, and macrophage activation syndrome (MAS).
  • Criteria for tapering corticosteroids were established, focusing on fever resolution, improved physical functioning, and laboratory markers.
  • A defined corticosteroid tapering schedule was developed.

Conclusions:

  • The expert panel achieved consensus on corticosteroid management, resulting in an algorithm accepted by RAPPORT investigators.
  • The developed algorithm effectively standardized steroid dosing within the RAPPORT trial.
  • Further research is needed to evaluate the algorithm's broader applicability in clinical practice.